Artelo biosciences receives $3.0 million in net proceeds from exercise of warrants

La jolla, calif., feb. 08, 2021 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the exercise of a portion of the warrants from its october 2020 financing. existing investors agreed to exercise warrants for net proceeds of approximately $3 million.
ARTL Ratings Summary
ARTL Quant Ranking